Trump’s HHS Deputy Pick Previously Urged Drug Approval Reform, Opposed FDA Reg Of LDTs, Algorithms

By Jessica Karins / November 27, 2024 at 1:35 PM

President-elect Donald Trump’s pick for HHS deputy -- Jim O’Neill, an executive with ties to Silicon Valley and a former HHS official during George W. Bush’s administration -- once made waves by suggesting FDA should consider only the safety of drugs in approval decisions, leaving efficacy as a post-market consideration.


Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.